Funding for this research was provided by:
Northern Ontario Academic Medicine Association (A-17-05)
Received: 6 May 2020
Accepted: 9 July 2020
First Online: 23 July 2020
Ethics approval and consent to participate
: This study was approved by the Research Ethics Board of Laurentian University in Sudbury, Ontario, Canada.
: This study only used administrative health data, there was no primary data collection; therefore, consent for publication from individual patients did not apply.
: Dr. David Marsh maintains the following roles: Chief Medical Director at CATC (Canadian Addiction Treatment Center), opioid agonist therapy provider. Dr. Marsh has no ownership stake in the CATC as a stipendiary employee. We do not foresee any conflict of interest as data will be made freely available to the public, and neither the CATC nor the Universities prevent publication and dissemination of knowledge. The authors have no conflicts declared. This does not alter our adherence to the Harm Reduction Journal’s policies on sharing data and materials